Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Extract
Angle PLC Parsortix study uncovers targets in TNBC patients
Source: RNS Non-Regulatory
TIDMAGL
Angle PLC
11 May 2021
For immediate release 11 May 2021
ANGLE plc ("the Company")
NEW PARSORTIX STUDY UNCOVERS THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER
great comment in todays RNS
"Using ANGLE's marker-independent Parsortix system for CTC-enrichment, coupled with the DEPArray™ system for automated single-CTC retrieval following harvest by Parsortix, the authors showed that, in the vast majority of recurrent cancer cases, CTCs identified were non-epithelial and would not have been detected by any of the commercially available epithelial antibody-based approaches, including the market leader."
*cough cough* ex market leader;)
todays study also supports what was discussed by Mesenchymal makers at the ASCR conference last month.
https://www.biopharma-reporter.com/Article/2021/04/12/Positive-study-results-said-to-support-deployment-of-assay-system-in-cancer-drug-clinical-trials
could be a new exciting revenue steadm adding to a already solid company whos starting their growth stage.
Nail on the head their Lou. Parsortix is carving out its own market leading biomarkers in areas that its competitors are either unable to address on an individual level leading to multiple tests and therefore an increase in cost, or that it’s an unmet need.
first one of the expected two I mentioned last week - intriguing new application offering new revenue streams. They are going to need more clinics.
And THIS isn't even the big news re. the FDA additional submission that we are expecting to drop at anytime. Apologies for being boring but I am going to repost the following because it explains the excitement behind the technology and its life-saving potential for so many cancer patients.
There are only two things that prospective new investors need to look at here. Firstly, the following presentation which outlines the unique and highly exciting technology and its huge potential market:
https://www.youtube.com/watch?v=dmihuELlhDM&t=5s
Secondly, how rapidly ANGLE PLC is moving forward and how we have already done since that presentation:
https://www.lse.co.uk/rns/AGL/preliminary-results-bz4lz37r3tmhatw.html
Researcher - Angle are going to need more clinics
Well I am going to need more shares!
agreed. what blows my mind is the current market leaders have a 3-5% chance of successfully collecting CTCs based on the epithelial approach. and these are market leaders! parsortix can harvest CTCs for analysis in the high 90s.
it isnt even a close % of success. its like trying to drive a car with no legs, no arms, blind, with no steering wheel and no car!!!
big chunk of the pie AGL is soon to be getting. magor ramp up in revenue and profit in coming years (before theyre bought out anyway)
another piece of the jigsaw ,at some point the realisation will dawn on people .
i like many intend to buy more at every oppurtunity also portage biotech
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company,
at some point it will go from A to THE if not already there !!
I've always felt that buy-outs are overstated on these boards for purposes of ramping but I am genuinely hoping and praying this doesn't happen here. ANGLE is such an exciting prospect in the infancy of commercialisation and it would just be great to be a part of its growth. Safe to say, I'm a fan :)
Yes PJ,
Last year I made a bomb on SNG. This year it is Angle. Difference with Angle is it has legs that will carry it all the way for many many years. Surely more value for investors if it is not sold.
it's an important point Bojo - many trader types will consider selling on FDA approval, but it is the starting block not the finish line.
This is great news, and just underpins the great story that is AGL.
I'm so tempted to buy more. I have 80% of my PF in what should be safe but sound funds, but given the lacklustre performance the last few months, its always tempting to change the ratio and drop to 70% in funds, and have another 10% to use in higher risk stocks.
Decisions, decisions.
I know, don't risk more than you can afford to lose.
"don't risk more than you can afford to lose.".....
Agree, but there are some companies where you are willing to take more risk through being willing and able to hang-on for the longer term in the face of an unexpected short / medium term drop, as could potentially happen with the wider market. It's not just about s*** or bust. I don't see AGL as being the type of company that the original adage applies to - as with some oil & miners - at least, not without my caveat.
"don't risk more than you can afford to lose.".....
Agree, but there are some companies where you are willing to take more risk through being willing and able to hang-on for the longer term in the face of an unexpected short / medium term drop, as could potentially happen with the wider market. It's not just about s*** or bust. I don't see AGL as being the type of company that the original adage applies to - as with some oil & miners - at least, not without my caveat.
I liked my post so much that I posted it twice ;) Apologies.
Put another way, even if we were to take a hit on FDA approval, AGL would still recover and excel on other service fronts, imo. DYOR.
and what kind of hit might that be PJT?
FDA have worked with the company through an interactive Q submission for over three years.
They have assessed the whole application, then sent a request for more detail, which we trust the company will return shortly.
Are FDA at that point going to say "oh, sorry, the application has been rejected"?
The big danger for me was the De Novo status - I think FDA may have been justified in saying "product is good but we are not convinced about De Novo status" but they surely could not state this after a request for more detail?
so for me the only remaining danger is a further short delay - "extra detail insufficient, please provide more" and thus add another 6 weeks to the time frame and knock the share by 20% for a week or so.
The more pressing question for me, is when will the market start to move forward with the price in anticipation of the FDA decision which has been substantially derisked since notification of AIR?
To name but a few, IMM, STX and POLX all moved in anticipation to a more reasonable valuation prior to the inflection point. I expect the same to happen here, only to be assisted by commercial progress from the Pharma services side of the business.
Researcher how could FDA claim it's not de Novo, when it was for that reason the FDA rejected the 510k application
clearly we will need a timely resubmission confirmed first Div - then the 'anticipation' move up (which is already part of the current SP, we should remember) will be boosted by clinical news and probably another research paper. I would see the Broker target of 150p as an ideal launch pad, but we may not quite get that far - 140 ish would do me. FDA approval would then propel the SP toward £3, allowing it eventually to settle around £2.50 for the next phase of the grand plan toward £4, and then £8. (my top slice target price). Others I know see £10 and £12 and £20, which is entirely possible, but by then I'll have a modest holding.
Phantom, I don't believe they could - but my fear was they might respond: 'application doesn't meet the necessary high threshold for De Novo' or some such nonsense (if I'm being cynical). Now I don't feel they could.
De Novo just means there is not a similar product already approved that can be used as a comparison. If the FDA had not thought it de Novo it would have been approved years ago when the 510k submission was made.
agreed in terms of definition - but the application still would need to reach demanding de Novo standards....
anyway, we both agree that this no longer applies, I'm no longer worried about it, and perhaps my earlier fears were unfounded :-)